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Abstract: The association between interleukin (IL)-6 promoter polymorphism (-174 G/C), circulating
IL-6 levels and mortality in septic patients has scarcely been addressed, and then only in studies of
small sample size, and a direct association among them has not been previously reported. Therefore,
the purpose of our study was to determine whether this association exists. An observational,
prospective and multicenter study including severe septic patients was undertaken and serum
IL-6 levels at severe sepsis diagnosis and IL-6 promoter polymorphism (-174 G/C) were determined.
The end-point of the study was 30-day mortality. The study included 263 patients with the following
genotypes of IL-6 promoter polymorphism (-174 G/C): 123 (46.8%) GG, 110 (41.8%) GC and
30 (11.4%) CC. CC homozygous patients showed lower sepsis-related organ failure assessment
(SOFA) score, serum IL-6 levels and mortality at 30 days compared to those with other genotypes
(GC or GG). On regression analysis, CC homozygous patients showed lower 30-day mortality than
those with genotype GG (odds ratio = 0.21; 95% CI = 0.053−0.838; p = 0.03) or GC (hazard ratio = 0.28;
95% CI = 0.074−1.037; p = 0.06). The most important results of our study were that CC might be
a favorable genotype in septic patients showing lower serum IL-6 levels and lower risk of death
within 30 days.
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1. Introduction
Sepsis is a major cause of mortality and resource consumption [1,2]. Interleukin (IL)-6 is one of
several pro-inflammatory cytokines involved in systemic response [3]. Higher circulating IL-6 levels
have been reported in non-surviving rather than surviving septic patients [4–8].
An association between IL-6 promoter polymorphism (-174 G/C) and prognosis has been
found in different diseases [9–13]. In addition, an association between IL-6 promoter polymorphism
(-174 G/C) and circulating IL-6 levels has been found in different diseases [11–17]. The influence of IL-6
promoter polymorphism (-174 G/C) on sepsis risk and sepsis-related mortality has been addressed
in some studies [18–29], but a recently published meta-analysis found no association between this
polymorphism and sepsis-related mortality [30]. However, in most of those studies the sample size
was small and circulating levels of IL-6 were not reported. Therefore, the purpose of our study was to
determine whether there is an association between IL-6 promoter polymorphism (-174 G/C), serum
levels of IL-6 and 30-day mortality in a large series of adult septic patients.
2. Results
The study included 263 severe septic patients with the following genotypes of IL-6 promoter
polymorphism (-174 G/C): 123 (46.8%), with genotype GG, 110 (41.8%) with genotype GC and
30 (11.4%) with genotype CC. No significant difference in Hardy-Weinberg equilibrium was found
between the genotypes of our series (chi-square = 0.20; p = 0.66).
We found that 223 (84.8%) patients showed septic shock, that in 132 (50.2%) patients all cultures
were sterile, and that 86 (32.7%) patients were dead at 30 days. We do not find statistically significant
differences between patient groups in sex, age, diabetes mellitus, ischemic heart disease, chronic
obstructive pulmonary disease (COPD), microorganism responsible, site of infection, bloodstream
infection, empiric antimicrobial treatment, septic shock at the time of enrolment in the study, creatinine,
leukocyte count, bilirubin, lactic acid, platelets, international normalized ratio (INR), and activated
partial thromboplastin time (aPTT). However, CC homozygous patients showed higher PaO2/FIO2,
and lower sepsis-related organ failure assessment (SOFA) score, serum IL-6 levels and mortality at
30 days (Table 1). All cases of 30-day mortality were due to sepsis. In addition, we found that CC
homozygous patients showed lower serum IL-6 levels than patients with genotypes GG (p < 0.001) or
GC (p < 0.001), and that patients with genotypes GC showed lower serum IL-6 levels than patients
with genotypes GG (p = 0.003) (Figure 1).
Table 1. Characteristics of septic patients according to genotype of IL-6 promoter polymorphism
(-174 G/C).
Demographic and Clinical Characteristics GG (n = 123) GC (n = 110) CC (n = 30) p-Value
Bloodstream infection—n (%) 17 (13.8) 22 (20.0) 3 (10.0) 0.28
COPD—n (%) 15 (12.2) 14 (12.7) 6 (20.0) 0.52
Diabetes mellitus—n (%) 39 (31.7) 34 (30.9) 6 (20.0) 0.44
Empiric antimicrobial treatment—n (%) – – – 0.28
Unknown whether adequate due to negative
cultures 63 (51.2) 52 (47.3) 17 (56.7) –
Unknown whether adequate due to diagnosis by
antigenuria 5 (4.1) 1 (0.9) 1 (3.3) –
Adequate 45 (36.6) 52 (47.3) 11 (36.7) –
Inadequate 11 (8.9) 4 (3.6) 1 (3.3) –
Female gender—n (%) 43 (35.0) 35 (31.8) 12 (40.0) 0.69
Ischemic heart disease—n (%) 16 (13.0) 9 (8.2) 4 (13.3) 0.46
Mechanical ventilation—n (%) 104 (84.6) 95 (86.3) 24 (80.0) 0.51
Microorganism responsible—n (%) – – – –
Unknown 63 (51.2) 52 (47.3) 17 (56.7) 0.63
Gram-positive 28 (22.8) 30 (27.3) 7 (23.3) 0.72
Gram-negative 32 (26.0) 27 (24.5) 8 (26.7) 0.96
Fungii 6 (4.9) 1 (0.9) 0 0.11
Anaerobe 1 (0.8) 1 (0.9) 0 0.88
Mortality at 30 days—n (%) 47 (38.2) 36 (32.7) 3 (10.0) 0.01
Septic shock—n (%) 104 (84.6) 95 (87.2) 24 (80.0) 0.60
Int. J. Mol. Sci. 2016, 17, 1861 3 of 10
Table 1. Cont.
Demographic and Clinical Characteristics GG (n = 123) GC (n = 110) CC (n = 30) p-Value
Site of infection—n (%) – – – 0.84
Respiratory 64 (52.0) 67 (60.9) 14 (46.7) –
Abdominal 39 (31.7) 28 (25.5) 10 (33.3) –
Neurological 4 (3.3) 1 (0.9) 0 –
Urinary 6 (4.9) 5 (4.5) 2 (6.7) –
Skin 5 (4.1) 4 (3.6) 2 (6.7) –
Endocarditis 5 (4.1) 4 (3.6) 2 (6.7) –
Osteomyelitis 0 1 (0.9) 0 –
Age—median years (p25–75) 56 (43–68) 61 (50–70) 63 (51–78) 0.32
APACHE-II score—median (p25–75) 20 (15–25) 21 (16–25) 20 (17–22) 0.62
aPTT (seconds)—median (p25–75) 35 (29–44) 33 (28–43) 28 (27–43) 0.09
Bilirubin (mg/dl)—median (p25–75) 0.90 (0.50–2.49) 0.80 (0.41–1.50) 0.80 (0.51–1.63) 0.20
Creatinine (mg/dl)—median (p25–75) 1.30 (0.70–2.28) 1.40 (0.90–2.45) 1.60 (0.90–2.55) 0.94
Hospitalization before enrollment in the study
(days)—median (p25–75)
0 (0–5) 0 (0–5) 0 (0–3) 0.20
GCS—median (p25–75) 15 (13–15) 15 (8–15) 14 (10–15) 0.40
Interleukin-6 levels (pg/mL)—median (p25-75) 429 (74–1034) 136 (41–852) 21 (13–116) <0.001
INR—median (p25–75) 1.42 (1.20–1.71) 1.20 (1.06–1.50) 1.36 (1.11–1.50) 0.0033
Lactic acid (mmol/L)—median (p25–75) 2.15 (1.13–4.38) 2.20 (1.25–4.45) 2.00 (1.15–3.15) 0.11
Leukocytes (cells/mm3)—median × 103 (p25–75) 14.1 (8.9–20.1) 15.2 (7.9–22.0) 16.2 (13.4–22.4) 0.57
Pa02/FI02 ratio—median (p25–75) 194 (111–265) 160 (102–221) 250 (172–298) 0.001
Platelets (cells/mm3)—median × 103 (p25–75) 165 (90–243) 179 (101–270) 210 (93–267) 0.17
SOFA score—median (p25−75) 10 (7–13) 10 (7–12) 8 (6–11) 0.02
COPD = chronic obstructive pulmonary disease; APACHE = Acute physiology and chronic health evaluation;
aPTT = Activated partial thromboplastin time; GCS = Glasgow coma scale; INR = International normalized
ratio; PaO2/FIO2 = pressure of arterial oxygen/fraction inspired oxygen; SOFA = Sepsis-related organ failure
assessment; p25–75 = percentile25–75.
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Figure 1. Serum interleukin-6 levels accor i e f I -6 promoter polymorphism
(-174 G/C).
Kaplan-Meier analysis showed differences in mortality at 30 days between different genotypes
(p = 0.02) (Figure 2). We found that CC homozygous patients showed lower risk of mortality at 30 days
than patients with genotypes GC (hazard ratio = 0.18; 95% CI = 0.05−0.62) or GG (hazard ratio = 0.23;
95% CI = 0.06−0.80), and we do not find statistically significant differences between GC and GG
genotypes (hazard ratio = 0.78; 95% CI = 0.46−1.35).
On regression analysis, CC homozygous patients showed lower 30-day mortality than those
with genotype GG (odds ratio = 0.21; 95% CI = 0.053−0.838; p = 0.03) or GC (hazard ratio = 0.28;
95% CI = 0.074−1.037; p = 0.06) after controlling for age, baseline measures of SOFA score and serum
lactic acid levels (T ble 2). In addition, we found that serum IL-6 levels were ass ciated with hi her
mortality at 30 day (odds ratio = 1.001; 95% CI = 1.0001−1.001; p = 0.002) after controlling for age,
baseline measures of SOFA score and serum lactic acid levels.
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Table 2. Multiple logistic regression analyses to predict 30-day mortality.
Predictors Odds Ratio 95% Confidence Interval p-Value
First Model – – –
SOFA (points) 1.15 1.023–1.284 0.02
Lactic acid levels (mmol/L) 1.23 1.063–1.430 0.006
Age (years) 1.02 0.990–1.042 0.23
Genotype of interleukin-6 (CC vs. GG) 0.21 0.053–0.838 0.03
Second Model – – –
SOFA (points) 1.22 1.068–1.395 0.003
Lactic acid levels (mmol/L) 1.08 0.933–1.254 0.30
Age (years) 1.02 0.988–1.052 0.22
Genotype of interleukin-6 (CC vs. GC) 0.28 0.074–1.037 0.057
Third Model – – –
SOFA (points) 1.16 1.062–1.263 0.001
Lactic acid levels (mmol/L) 1.14 1.029–1.033 0.01
Age (years) 1.01 0.993–1.033 0.22
Serum interleukin-6 levels (pg/mL) 1.001 1.0001–1.001 0.002
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The influence of IL-6 promoter polymorphism (-174 G/C) on sepsis risk and sepsis mortality
has been addressed in some studies [18–29]. A recently published meta-analysis found no
association between IL-6 promoter polymorphism (-174 G/C) and sepsis-related mortality [30].
In addition, another two studies were publis ed after the meta-analysis [18,19]. In children with
community-acquired pne monia (CAP), Zidan et al. found that patients with genotype GG sho ed
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a lower risk of early mortality [19]. In 277 Chinese patients with severe pneumonia-induced sepsis,
Feng et al. found no association between IL-6 promoter polymorphism (-174 G/C) and mortality [18].
Most previous studies had a small sample size (fewer than 200 patients) and circulating levels of
IL-6 were not reported. Only three studies had a sample size higher than 200 patients (277, 306 and
1135 patients, respectively) [18,22,23]. Rodriguez-Gallego et al. did not find an association between that
polymorphism and mortality in patients with CAP [23]; and in another study, the same team found that
pneumococcal CAP patients with genotype GG had a lower risk of death [22]. Our finding of lower
mortality in CC homozygous severe septic patients contradict those of Rodriguez-Gallego et al. [22]
and Feng et al. [18]. The discrepancy between study findings could be due to differences in
ethnicity (European, African, Asian), age (adult, pediatric, neonatal), type of infection (sepsis, CAP,
meningococcemia, pneumococcal infection), and severity of infection (sepsis, severe sepsis, septic
shock). Rodriguez-Gallego et al. found that patients with genotype GG had a lower risk of early
death [22]; their study included patients with pneumococcal CAP who had a rate of septic shock of
19.9%, and 5% mortality at 28 days. Feng et al. did not find an association between IL-6 promoter
polymorphism (-174 G/C) and mortality [18]; they included patients with severe pneumonia-induced
sepsis, mean SOFA score of 5 points, microorganism responsible for pneumonia isolated in 38.6%,
a rate of septic shock of 34.7%, and a mortality rate of 22.7%. Our study included patients with
severe sepsis with different sites of infection (55% respiratory, 29% abdominal and 16% others),
mean SOFA score of 9 points, microorganism responsible for sepsis isolated in 50.2%, rate of septic
shock of 84.7%, and 33% of patients had died at 30 days. Our finding of lower early mortality in
CC homozygous severe septic patients are in consonance with that of Balding et al. who studied
183 children with meningococcemia and they too found lower early mortality in CC homozygous
patients [29]. In addition, other authors have reported better prognosis in CC homozygous patients of
IL-6 promoter polymorphism (-174 G/C) in various diseases, such us different types of cancer, surgical
coronary revascularization and end-stage renal disease on hemodialysis [10–14].
An interesting finding in our series of severe septic patients was the association between IL-6
promoter polymorphism (-174 G/C) and serum levels of IL-6. This association has scarcely been
addressed in septic patients [19,21,26,31], and then only in studies of small sample size, the largest
being 112 severe septic patients in a study by Tischendorff et al. [31]. Two of the above studies reported
higher circulating levels of IL-6 in patients with genotype GG [26,31]; however, an association between
IL-6 promoter polymorphism (-174 G/C) and survival was not found. In addition, another two of
those studies found higher early mortality in GG patients than in those with other genotypes [19,21];
however, they did not find an association between IL-6 promoter polymorphism (-174 G/C) and
circulating levels of IL-6. Thus, our finding of lower serum IL-6 levels in patients with CC genotype
than in those with other genotypes is in consonance with that previously reported [26,31], and our
study included a higher sample size (263 patients). In addition, other studies have reported lower
circulating levels of IL-6 in CC homozygous patients with different types of cancer, arthritis, cirrhosis,
pancreatitis, retinal idiopathic Eales’s vasculitis, surgical coronary revascularization and end-stage
renal disease on hemodialysis [12–18].
Another interesting finding of our study was the association between circulating IL-6 levels and
early mortality in severe septic patients. We found higher serum IL-6 levels in non-survivors than in
surviving patients, in agreement with previous studies [5–9].
To our knowledge, this is the first study to report an association between IL-6 promoter
polymorphism (-174 G/C), circulating levels of IL-6 and early mortality in septic patients. As previously
mentioned, other authors have reported better prognosis in CC homozygous patients, including
children with meningococcemia [29] and adults with non-infectious diseases [10–14]. Also, lower
circulating levels of IL-6 have been found in CC homozygous patients with sepsis [26,31] and other
non-infectious diseases [12–18]. Lastly, lower serum IL-6 levels have been reported in non-surviving
than surviving septic patients [5–9]. We found that the lower 30-day mortality rate and serum
IL-6 levels were presented by patients with genotype CC, followed by GC patients and finally
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by GG patients. Thus, a possible explanation for our findings is that CC homozygous patients
had lower circulating levels of IL-6; they therefore presented a lower inflammatory response with
lower sepsis severity (reflected by a lower SOFA score) and finally, lower risk of death. There are
contradictory reports about the role of IL-6 polymorphisms in infectious diseases. The inflammatory
response, particularly IL-6 production, varies greatly depending on the causative pathogen and the
route of infection [32,33]. In the context of compartmentalized infections, as in many patients with
pneumococcal pneumonia, the IL-6 -174 GG genotype (associated with higher IL-6 production) may
be protective against severe complications, as previously reported by Rodriguez-Gallego et al. [22].
In contrast, the CC genotype (associated with lower IL-6 production) may be protective against
inflammatory response in severe septic patients, according to the results of our study.
The frequencies of the IL-6 promoter polymorphism (-174 G/C) genotypes in our septic patients
(46.8% with GG, 41.8% with GC and 11.4% with CC genotype) are similar to those found by
Rodriguez-Gallego et al. (46.8% with GG, 42.6% with GC and 10.5% with CC genotype) [23].
Our study has certain limitations. First, we determined only one genetic polymorphism. It is
difficult that a single nucleotide polymorphism (SNP) of a proinflammatory cytokine gene might be
relevant for critical patient outcome [34]; however, our sample size was sufficiently large to show an
association between the IL-6 promoter polymorphism (-174 G/C) and early mortality. Regardless,
the determination of genetic polymorphisms of other cytokines (such as tumor necrosis factor, IL-1,
IL-10) could be interesting; Second, we did not determine IL-6 promoter polymorphism (-174 G/C) in
non-septic critically ill patients or healthy control subjects; however, our purpose was to determine
whether there is an association between the polymorphism and sepsis survival, not to analyze the
association between the polymorphism and the appearance of sepsis; Third, the sample size in
the group of patients with the CC genotype was low; however, it was sufficiently large to show
an association between the IL-6 promoter polymorphism (-174 G/C), serum IL-6 levels and early
mortality; Fourth, we did not report data on treatments and treatment response over time; Fifth,
our study cohort was a heterogeneous group of septic patients with different sites of infection and
microorganisms responsible for infection; Sixth, we did not record the exact moment when blood
samples were obtained, nor the time interval between the onset of symptoms and blood sampling;
Seventh, blood samples were immediately stored at −80 ◦C until the determinations; however, they
were not placed on ice during the time to storage; Eighth, we have not collected the number of patients
removed from the study due to different causes (patients declining participation, more than two hours
since the diagnosis, exclusion criteria, etc.).
4. Materials and Methods
4.1. Design and Subjects
A multicenter, prospective and observation study was carried out between 2008–2009 with
263 severe septic patients from six Intensive Care Units of Spain. Institutional Review Boards of
the following six participating hospitals approved the study: Hospital Insular (Las Palmas de Gran
Canaria), Hospital Clínico Universitario de Valencia (Valencia), Hospital Universitario de Canarias
(La Laguna. Tenerife), Hospital Universitario Dr. Negrín (Las Palmas de Gran Canaria), Hospital
Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife), Hospital San Jorge (Huesca).
Written informed consent was obtained from patients or their family members.
We included patients diagnosed with septic shock or severe sepsis according to the International
Sepsis Definitions Conference [35]. We excluded patients with steroid, immunosuppressive or radiation
therapy, hematologic or solid tumor, white blood cell count <1000/mm3, human immunodeficiency
virus (HIV), age <18 years, pregnancy, or lactation.
The same cohort of severe septic patients was used in previous publications by our team for other
objectives [36–39]. In the current research, we sought to determine whether there is an association
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between IL-6 promoter polymorphism (-174 G/C), serum levels of IL-6 and 30-day mortality in a large
series of adult septic patients.
4.2. Variables Recorded
Bloodstream infection, diabetes mellitus, chronic obstructive pulmonary disease (COPD), empiric
antimicrobial treatment, ischemic heart disease, microorganism responsible, sex, site of infection,
age, bilirubin, activated partial thromboplastin time (aPTT), sepsis-related organ failure assessment
(SOFA])score [40], international normalized ratio (INR), lactic acid, creatinine, leukocytes, platelets,
fraction inspired of oxygen (FiO2), pressure of arterial oxygen (PaO2) were recorded for all patients.
The end-point of the study was 30-day mortality. We used serum separator tubes (SST) for the
determination of bilirubin and creatinine, citrated plasma tubes for the determination of activated partial
thromboplastin time (aPTT) and international normalized ratio (INR), and ethylenediaminetetraacetic
acid (EDTA)-containing tubes for the determination of leukocyte and platelet counts.
Empiric antimicrobial therapy was considered adequate if the microorganism responsible for
sepsis was susceptible to at least one of the antimicrobial agents used, inadequate if the microorganism
responsible for sepsis was not susceptible to any antimicrobial agent used, and unknown whether
adequate when it was not possible to know whether the microorganism responsible for sepsis was
susceptible to any antimicrobial agent used (in cases of sterile cultures or diagnosis by antigenuria).
4.3. Blood Samples and Determinations
We collected venous blood samples at diagnosis of severe sepsis (within the first two hours of
diagnosis of severe sepsis) for the determination of serum IL-6 concentration and genetic polymorphism
of IL-6, and the samples were immediately stored at −80 ◦C until the determinations.
The determination of IL-6 promoter polymorphism (-174 G/C) (rs1800795) was carried out
in the Research Unit of Hospital Universitario de Canarias (La Laguna, Santa Cruz de Tenerife,
Spain). We performed genotyping by polymerase chain reactions (PCR) and restriction fragment
length polymorphism (RFLP) analysis. We prepared DNA from 3 mL of peripheral blood using
treatment with proteinase K, extraction of phenol-chloroform extraction and precipitation of ethanol.
We used approximately 100 ng DNA as the template in PCR using the following primers, flanking
the -174 G/C polymorphism (rs1800795) of the IL-6 gene: 5′-TTGTCAAGACATGCCAAAGTG-3′
and 5′-TCAGACATCTCCAGTCCTATA-3′, and the temperature profile: 94C-52C-72C, 30 s each,
for 30 cycles. We restricted the amplified DNA with endonuclease NIa III (CATG) (New England
Biolabs, Boston, MA, USA) for two hours at 37 ◦C. The resulting DNA fragments were separated by
gel electrophoresis in 2% agarose gel and visualized under ultraviolet light. In the absence of a NlaIII
site, a fragment of 300 bp was detected (G allele), whereas fragments of 169 and 131 bp corresponded
to the C allele.
The determination of serum levels of IL-6 concentrations was carried out in the Laboratory
Department of Hospital Universitario de Canarias (La Laguna, Santa Cruz de Tenerife, Spain) using
the kit IMMULITE (Siemens Healthcare Diagnostics Products Ltd., LLanberis, Gwynedd, UK), which is
a solid-phase, enzyme-labeled, chemiluminescent sequential immunometric assay. The inter-assay
coefficient of variation (CV) was 5.1%–7.5%, the intra-assay CV was 3.5%–6.2%; and the limit of
detection was 2 pg/mL.
4.4. Statistical Methods
We recorded categorical variables as frequencies and percentages, and we compared them between
groups by chi-square test. We recorded continuous variables as medians and interquartile ranges,
and we compared them between groups by Kruskall-Wallis test. To determine the association of IL-6
promoter polymorphism (-174 G/C) with mortality at 30 days (controlling for SOFA score, serum
lactic acid levels and age) a confirmatory multivariate logistic regression analysis with comparisons
of pair to pair genotypes was used. In addition, we also carried out a multivariate logistic regression
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analysis to determine the association of serum IL-6 levels with mortality at 30 days after controlling
for SOFA score, serum lactic acid levels and age. The clinical impact for the predictor variables was
calculated by odds ratio (OR) and 95% confidence intervals (CI). We plotted 30-day survival curves of
patient groups with CC, GC and GG genotypes using the Kaplan-Meier method and we compared
them using log-rank test. We tested the Hardy-Weinberg equilibrium in the genotypes of our series
using the chi-square test. P-values of less than 0.05 were considered statistically significant. NCSS 2000
(Kaysville, UT, USA) and SPSS 17.0 (SPSS Inc., Chicago, IL, USA) were used for statistical analyses.
5. Conclusions
To our knowledge, the present study involved the largest sample size to date and is the first to
report an association between IL-6 promoter polymorphism (-174 G/C), serum IL-6 levels and early
mortality in septic patients. The most important results of our study were that CC might be a favorable
genotype in septic patients showing lower serum IL-6 levels and lower risk of death within 30 days.
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